.Attributes Medicine, Published online: 03 September 2024 doi:10.1038/ s41591-024-03223-zThis Viewpoint requires addition of people along with MASLD and also measurement of liver outcomes in cardio-- kidney-- metabolic trials, when data suggest mechanistically tenable advantages and scientific safety-- and lays out factors for trial design as well as governing commendation.